Close

SurModics to Webcast First Quarter 2014 Earnings Conference Call on January 30

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

By 2033, World Market For APIs Could Reach US$ 384 Billion

The worldwide active pharmaceutical ingredient market size happened to...

Market Forecast For Innovative Small Molecule Injectables

A Business Research Company report goes on to predict...

Forecast: Bioinformatics Industry Will Reach $31.71B By 2031

As per new market research that’s titled 'Bioinformatics Market...

SurModics Inc. a leading provider of surface modification and in vitro diagnostic technologies to the healthcare industry announced today that it will host a live webcast of its first quarter 2014 conference call on Thursday January 30 at 4:00 p.m. CT (5:00 p.m. ET). The Company will issue an earnings news release after the market closes that afternoon.

Gary Maharaj chief executive officer and Andy LaFrence vice president of finance and chief financial officer will recap the first quarter 2014 financial results and accomplishments. To access the webcast go to the investor relations portion of the Company’s website at www.surmodics.com the day of the conference call and click on the webcast icon.

An audio replay will be available beginning at 7:00 p.m. CT on Thursday January 30 until 7:00 p.m. CT on Thursday February 6 and can be accessed by dialing 800-406-7325 and entering conference call ID passcode 4663820. In addition the conference call audio and transcript will be archived on the Company’s website following the call.

About SurModics Inc.

SurModics’ mission is to exceed our customers’ expectations and enhance the well-being of patients by providing the world’s foremost innovative surface modification technologies and in vitro diagnostic chemical components. The Company partners with the world’s leading and emerging medical device diagnostic and life science companies to develop and commercialize innovative products designed to improve patient diagnosis and treatment. Core offerings include surface modification coating technologies that impart lubricity prohealing and biocompatibility capabilities; and components for in vitro diagnostic test kits and microarrays.

 

 

Latest stories